Literature DB >> 1336663

Production and characterization of monoclonal antibodies to three infectious bronchitis virus serotypes.

K Karaca1, S Naqi, J Gelb.   

Abstract

Three panels of monoclonal antibodies (MAbs) were prepared against the spike (S) proteins of infectious bronchitis virus (IBV) strains Arkansas 99, Connecticut 46, and Massachusetts 41. Based on enzyme-linked immunosorbent assay (ELISA), the MAbs were grouped into three categories: 1) group-specific, which reacted with a broad spectrum of homologous and heterologous IBV serotypes; 2) serotype-specific, which reacted only with strains of the homologous serotype; and 3) strain-specific, which reacted "selectively" with only certain strains of homologous and heterologous serotypes. MAbs that displayed serotype specificity were all specific to S1 fractions of the homologous serotype, confirming that epitopes that determine virus serotype are associated with the S1 protein. An excellent correlation was found when the results of IBV serotyping by MAb-based indirect ELISA were compared with those from the conventional virus-neutralization test. This confirms that the MAbs described here will serve as valuable tools in epizootiological studies and serotype-specific diagnosis of IBV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336663

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  24 in total

1.  Analysis of the serotype-specific epitopes of avian infectious bronchitis virus strains Ark99 and Mass41.

Authors:  W Jia; X Wang; C R Parrish; S A Naqi
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  Infectious bronchitis virus S2 gene sequence variability may affect S1 subunit specific antibody binding.

Authors:  S A Callison; M W Jackwood; D A Hilt
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

3.  The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells.

Authors:  Victor C Chu; Lisa J McElroy; Vicky Chu; Beverley E Bauman; Gary R Whittaker
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.

Authors:  Sandrine Belouzard; Victor C Chu; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

5.  Sequence analysis of the gene coding for the S1 glycoprotein of infectious bronchitis virus (IBV) strains from New Zealand.

Authors:  Robin McFarlane; Ramneek Verma
Journal:  Virus Genes       Date:  2008-08-20       Impact factor: 2.332

6.  Bioinformatics and evolutionary insight on the spike glycoprotein gene of QX-like and Massachusetts strains of infectious bronchitis virus.

Authors:  Shahid Hussain Abro; Karin Ullman; Sándor Belák; Claudia Baule
Journal:  Virol J       Date:  2012-09-19       Impact factor: 4.099

7.  Comparison of SYBR green I real-time RT-PCR with conventional agarose gel-based RT-PCR for the diagnosis of infectious bronchitis virus infection in chickens in Morocco.

Authors:  Siham Fellahi; Mehdi El Harrak; Jens H Kuhn; Ghizlane Sebbar; El Arbi Bouaiti; Khadija Khataby; Ouafae Fassi Fihri; Mohammed El Houadfi; My Mustapha Ennaji
Journal:  BMC Res Notes       Date:  2016-04-22

8.  Histopathological and immunohistochemical study of air sac lesions induced by two strains of infectious bronchitis virus.

Authors:  A Bezuidenhout; S P Mondal; E L Buckles
Journal:  J Comp Pathol       Date:  2011-03-21       Impact factor: 1.311

9.  Sequence analysis of the S1 glycoprotein gene of infectious bronchitis viruses: identification of a novel phylogenetic group in Korea.

Authors:  Ji-Hyun Jang; Haan-Woo Sung; Chang-Seon Song; Hyuk-Moo Kwon
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

10.  Evolutionary implications of Avian Infectious Bronchitis Virus (AIBV) analysis.

Authors:  Peng Shi; Li Yu; Yun-Xin Fu; Jing-Fei Huang; Ke-Qin Zhang; Ya-ping Zhang
Journal:  Cell Res       Date:  2006-03       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.